Editorial - (2021) Volume 12, Issue 9
Date of Submission: 07-Sep-2021
, DOI: 10.37421/2157-7420.2021.12.381
Citation: Po- Tao Chen, "Cholesteryl Ester Transfer Protein (CETP) Targets Coronary Artery Disease. J Health Med Informat 12 (2021): 381
Copyright: Â© 2020 Chen PT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In almost 30 years since the introduction of HMG-CoA reductase inhibitors (statins), no other class of lipid modulators has entered the market. Elevation of High-Density Lipoprotein-Cholesterol (HDL-C) via inhibiting Cholesteryl Ester Transfer Protein (CETP) is an attractive strategy for reducing the risk of cardiovascular events in high-risk patients. Transfer of triglyceride and Cholesteryl Ester (CE) between lipoproteins is mediated by CETP; thus inhibition of this pathway can increase the concentration of HDL-C.
Torcetrapib was the first CETP inhibitor evaluated in phase III clinical trials. Because of off-target effects, torcetrapib raised blood pressure and increased the concentration of serum aldosterone, leading to higher cardiovascular events and mortality. Torcetrapib showed positive effects on cardiovascular risk especially in patients with a greater increase in HDL-C and apolipoprotein A-1 (apoA-1) levels. The phase III clinical trial of dalcetrapib, the second CETP inhibitor that has entered clinical development, was terminated because of ineffectiveness.
Dalcetrapib is a CETP modulator that elevated HDL-C levels but did not reduce the concentration of Low-Density Lipoprotein Cholesterol (LDL-C). Both heterotypic and homotypic CE transfer between lipoproteins are mediated by some CETP inhibitors, including torcetrapib, anacetrapib, and evacetrapib, while dalcetrapib only affects the heterotypic CE transfer. Moreover, dalcetrapib is a pro-drug that must be hydrolyzed to a pharmacologically active thiol form. Two other CETP inhibitors, anacetrapib and evacetrapib, are currently undergoing evaluation in phase III clinical trials. Generally, the concentration of HDL-C has been considered a biomarker for the activity of CETP inhibitors. However, it is not clear whether a fundamental relationship exists between HDL-C levels and the risk of coronary artery diseases. The most crucial role for HDL is cholesterol efflux capacity in which HDL can reverse transport cholesterol from foam cells in atherosclerotic plaques. In view of the heterogeneity in HDL particle size, charge, and composition, the mere concentration of HDL-C may not be a good surrogate marker for HDL functionality.
Epidemiologic studies have shown that the concentration of High-Density Lipoprotein Cholesterol (HDL-C) is a strong, independent, inverse predictor of coronary heart disease risk. This identifies HDL-C as a potential therapeutic target. Compared with Low-Density Lipoprotein Cholesterol (LDL-C)- lowering agents, however, currently available HDL-raising drugs are relatively ineffective. Consequently, recent years have seen considerable efforts expended on identifying new drugs that can raise HDL-C. Cholesteryl Ester Transfer Protein (CETP) plays an important role in cholesterol metabolism, being responsible for the transfer of cholesteryl esters from HDL to very lowdensity lipoproteins and LDLs.
The observation that Japanese populations with CETP deficiency exhibited high levels of HDL-C has led to the concept that drugs targeting CETP activity may elevate HDL-C levels and potentially decrease cardiovascular risk. Support of this proposition has been obtained in rabbits where inhibition of CETP activity is markedly antiatherogenic. Two CETP inhibitors—torcetrapib and JTT-705—are currently in the preliminary stages of clinical development. Initial studies with these drugs in humans show that they substantially increase HDL-C levels and modestly decrease LDL-C levels. Larger, long-term, randomized, clinical end point trials are required to determine whether the beneficial effects of CETP inhibitors on lipoprotein metabolism can translate into reductions in cardiovascular events.
Three CETP genotypes that are associated with moderate inhibition of CETP activity (and, therefore, modestly higher HDL-C levels) show weakly inverse associations with coronary risk. The ORs for coronary disease were compatible with the expected reductions in risk for equivalent increases in HDL-C concentration in available prospective studies.
In Western societies, cardiovascular disease is the main cause of illness and mortality. The augmentation of high density lipoprotein (HDL) levels in circulation is one of the most promising therapy options for preventing the onset and progression of cardiovascular disease, as high HDL levels have been proven to correlate negatively with the risk of cardiovascular disease. Inhibition of cholesteryl ester transfer protein leads to an increase in HDL levels (CETP).
HDL levels, risk of Coronary Artery Disease (CAD), and treatment responsiveness have all been linked to polymorphisms in and around the Cholesteryl Ester Transfer Protein (CETP) gene. These polymorphisms' mechanism of effect has yet to be determined. The genetic variations impacting CETP levels were identified using mRNA allelic expression and splice isoform assessments in human liver tissues. Several variations were strongly related with allelic CETP mRNA expression ratios in 56 human livers. Cholesteryl Ester Transfer Protein (CETP) is a protein that facilitates the exchange of neutral lipids (cholesteryl esters, triglycerides) and phospholipids between distinct lipoprotein fractions in human blood plasma. CETP inhibition has been demonstrated to boost High Density Lipoprotein (HDL) cholesterol while decreasing Low Density Lipoprotein (LDL) cholesterol, making CETP inhibition a promising target for preventing and treating cardiovascular disease.